Phase Space AI

Trade Construction

Harrow [HROW]

Harrow, Inc. [HROW] — Trade Construction & Liquidity

2026-07-29 · Spot $39.32 · No position verdict is issued. This document sizes and prices the vehicle if the book chooses to act.

---

1. Liquidity Criteria — equity

A $5m position is 16% of one day's ADV and exits comfortably inside three sessions at 30% participation. Equity liquidity: PASS. Size is constrained by volatility, not by tradability.

---

2. Liquidity Criteria — options: the actual chain, pulled live

Per the Criteria, no options structure may be proposed without the chain. Pulled from Alpaca 2026-07-29; 216 active contracts across four expiries. Full data in data/opts.json. Calls, $35–$60 strikes:

Findings. 1. Only the January-2027 expiry is investable. Open interest of 1,244–6,559 contracts at the 35/40/45/47/50/55 strikes is genuine size — this is not the HCA failure mode (18 contracts across an entire chain). October-2026 and March-2019 chains are too thin at the strikes that matter. 2. Spreads are wide everywhere. The tightest near-the-money quote is the Jan-27 $40 at 39% of mid; most are 50–90%. A defined-risk structure is fillable in modest size but expensive to cross, and any modelling must be done at the offer, not at mid. 3. Implied volatility is rich. Jan-2027 IV of 75–80% against 69.0% 252-day realised = ~1.10x realised. That is the ordinary variance-risk-premium configuration in which buying premium is systematically expensive. Spreads, not outright calls.

Options: PASS with caveat — a vehicle exists and can be filled, but the transaction cost is a first-order input, not a rounding item.

---

3. The vehicle, if the book converts

January-2027 $45 / $55 call debit spread. Chosen because the target ($50.00) sits inside the strikes, the expiry captures Q2-2026 (Aug), Q3-2026 (Nov), the QUELL readout (Q4-2026) and FY2026 results (~Mar-2027, one month after expiry — noted as a gap), and both legs carry >1,700 contracts of open interest.

• At mid ($2.46): 4.07x max return, break-even $47.46 (+20.7%).
• At the offer ($4.61): 2.17x max return, break-even $49.61 (+26.2%) — above the 12-month target of $50.00 by only 0.8%. This is the finding that matters. Crossing the full spread consumes essentially the entire modelled edge. The structure is only viable if filled meaningfully inside the quote — call it a $3.25–3.75 working limit, roughly 30–45% through the spread, and if it does not fill, it does not get done.
• Sizing at $3.50 debit: a 1.0% book position on a $10m book = $100k ≈ 286 contracts, versus 1,846 and 1,721 contracts of open interest. Feasible.

The straightforward alternative is common stock. At 69% realised volatility, inverse-volatility sizing does the risk work automatically, and the equity carries none of the ~40% round-trip friction.

---

4. Sizing, if converted

• Inverse-volatility sizing is the active protection on the Downside Criteria (which is MEASURED and blocks nothing). At 69.0% realised volatility versus a ~45% "high volatility" threshold, HROW sizes down by construction.
• Maximum 1.0–1.5% of book. At 69% volatility a −49% move to the $20 bear case is inside ~0.9 of a one-year sigma; a 1.0% position absorbs that within a 0.5%-of-book loss.
• The name is not additive to an existing MedTech/diagnostics book in a diversification sense but sits in a distinct sub-sector (Pharma, SIC 2834); the Sub-sector Criteria tag is recorded for concentration purposes.

5. Invalidation levels, if converted

6. What would repair the Valuation Criteria

The implied path fails by 12.6pp at a 12.0x exit multiple. It is repaired by price, not by argument:

• At $28.50 (−27.5%) the required CAGR at 12.0x falls to ~26%, i.e. the margin reaches zero against the demonstrated TTM rate.
• Alternatively, two consecutive quarters above $100m would move the demonstrated TTM YoY figure itself toward the high-30s and repair the margin without a price move — which is precisely what management is forecasting and precisely what has not yet happened. That is the honest conversion trigger.